Abstract Triple-negative breast cancers (TNBCs) are a group of aggressive breast cancers with a greater incidence of relapse, stage-for-stage, than ER/PR-positive and HER2-positive breast cancers, despite optimum loco-regional and systemic therapy. To date, no single targeted therapy has been approved for treatment of TNBC, and cytotoxic chemotherapy remains the standard systemic treatment. Recently, gene expression analysis identified six distinct TNBC subtypes, each with unique biology. In this review we discuss current and forthcoming therapeutic strategies and novel approaches to targeted treatment of these TNBC subtypes.
Introduction
Approximately 15 % of invasive breast cancers lack expression of estrogen and progesterone receptor (ER/PR) and HER2 (ERBB2); these are known as "triple-negative breast cancers" (TNBCs). Clinically, TNBCs are a group of aggressive breast cancers with a greater incidence of relapse, stagefor-stage, than ER/PR-positive and HER2-positive breast cancers. Despite optimum systemic chemotherapy, fewer than 30 % of women with metastatic breast cancer survive for five years, and virtually all women with metastatic TNBC will ultimately die of their disease. Vast improvements of disease-free and overall survival have been achieved for patients with non-TNBCs, largely because of the development of drugs that target the unifying alterations in these tumors, namely expression of ER/PR and overexpression of HER2. Such drugs as trastuzumab, pertuzumab, ado-trastuzumab, fulvestrant, tamoxifen, and aromatase inhibitors have all improved progression free and/or overall survival by targeting their respective receptors. The mainstay of treatment for TNBC, however, remains cytotoxic chemotherapy. The benefits of targeted therapy have largely eluded TNBCs, because the heterogeneity of the disease has not enabled the development of drugs to target this entire subset of breast cancer. In this review, we discuss the current understanding of the heterogeneity of TNBCs and clinical studies being undertaken to target this disease.
Understanding the Diversity of TNBC
The diversity of breast cancer was characterized in the seminal paper published by Perou et al. that categorized breast cancer into distinct "intrinsic subtypes" on the basis of gene expression profiling [1] . Most TNBCs are classified as the "basallike subtype", which is characterized by lack of ER/PR/HER2 expression and increased expression of cytokeratins 5 or 6, 14, and 17, P-cadherin, p53, and EGFR [2] [3] [4] [5] [6] . Mutations and genomic deletions in TP53 and pRB, and high proliferation indices are common in this subtype [7] [8] [9] . Although most TNBCs are basal-like, approximately 20-30 % of clinical TNBCs are not basal-like by microarray analysis, and a significant number of basal-like breast cancers express ER/PR or HER2 [10] [11] [12] .
Several more recent studies have helped to refine our understanding of TNBCs. The Cancer Genome Atlas (TCGA) Research Network analyzed primary breast cancers by use of six methods-genomic DNA copy number arrays, DNA methylation, exome sequencing, messenger RNA arrays, microRNA sequencing, and reverse-phase protein arrays [13] . TCGA examined the genomic heterogeneity of tumors by integrating information from all methods. The most frequent loss-of-function alterations in TNBC noted by TCGA analysis involve genes associated with DNA damage repair, including loss of TP53, RB1, and BRCA1 function [13] . Aberrant activation of the phosphatidylinositol 3-kinase (PI3K) signaling pathways was also frequent, and believed to be secondary to loss of negative regulators, for example the lipid phosphatases PTEN or INPP4B [14, 15] or activating mutations in PIK3CA [16] , with other genes in the PI3K/mTOR signaling network [2, 16] . Further confirmation that TNBCs are heterogeneous, possibly from their inception, comes from a study in which over 100 TNBCs were sequenced and analyzed at the time of diagnosis. A high incidence of TP53 mutations was observed, but 12 % of cases did not have somatic mutations in any established "driver" genes [17] .
Subtyping TNBC
Distinct subtypes of TNBC, termed "TNBCtype", were recently identified by gene-expression (GE) analysis [18•] . Each subtype has unique biology and, in in-vitro studies, responds optimally to different therapy. The TNBCs subtypes include two basal-like TNBC subtypes, one with cell cycle and DNA damage response GE profiles (BL1) and the other enriched in growth factor signaling and myoepithelial markers (BL2), two mesenchymal subtypes with high expression of genes involved in differentiation and growth factor pathways (M and MSL), an immunomodulatory (IM) type, and a luminal subtype driven by androgen signaling (luminal androgen receptor, LAR) [18•] . Furthermore, TNBCtype was used to identify TNBC cell lines that were representative of these subtypes. "Driver" signaling pathways were pharmacologically targeted among these cell lines as proof-of-concept and to generate pre-clinical data on which to base future clinical trial design.
A recent retrospective analysis of correlation of pathologic response of 130 TNBCs treated with neoadjuvant doxorubicin, cyclophosphamide, and paclitaxel with different TNBC subtypes by TNBCtype GE expression was performed by Masuda et al. [19] . The highest pathologic complete response (pCR) (52 %) was observed for the BL1 subtype; response was lowest for the BL2, LAR, and MSL subtypes (0, 10, and 23 %, respectively). TNBCtype was also shown, by a likelihood ratio test, to be an independent predictor of pCR status (p=0.022) [19] . Such findings suggest that patients with TNBC should be assigned to different therapy on the basis of their disease subtype.
Targeting Basal-Like TNBCs

Platinum Salts
Numerous similarities have been noted for tumors arising in BRCA1 carriers and basal-like sporadic breast tumors, including greater likelihood of being ER/PR-negative, HER2-negative, and a high frequency of p53 mutations [20] . Basal keratins are expressed by both sporadic basal-like tumors and tumors with BRCA1 mutations, and both groups cluster together on gene expression profiling [20] . Similar to BRCA1-mutated tumors, basal-like TNBCs are notable for EGFR expression, c-MYC amplification, TP53 mutations, loss of RAD51-focus formation, genomic instability, and sensitivity to DNA-crosslinking agents [21] .
The DNA damage response GE profiles seen for BL1 TNBCs provide further evidence of the similarity of this subtype to BRCA1-mutated breast cancers and indicate ways of targeting BL1 TNBCs. Platinum salts, including carboplatin and cisplatin, lead to DNA cross-link strand breaks, which may be especially important in cells which are deficient in homologous recombination repair mechanisms, for example BRCA-mutated cells and BL1 TNBCs.
Clinically, initial evidence of the activity of platinum agents against TNBC has been demonstrated in two phase II studies. Silver et al. showed activity of neoadjuvant cisplatin as a single agent for treatment of 29 patients with locally advanced TNBCs. The pCR observed was 22 %; 50 % of patients had a partial response and 14 % had a complete response [22] . In another small study, 9 of 10 patients with stage I-III breast cancer harboring BRCA1 mutations achieved pathological complete remission after neoadjuvant therapy with cisplatin [23] .
Further evidence of the activity of platinum agents against TNBC comes from two large phase II randomized trials in the neoadjuvant setting: the GeparSixto phase II randomized trial, in its TNBC subset, compared neoadjuvant paclitaxel, liposomal doxorubicin, and bevacizumab with the same regimen with addition of carboplatin. The pCR improved from 37.9 % to 58.7 % on addition of carboplatin. However, only approximately 50 % of patients were able to complete treatment because of adverse events (possibly because all chemotherapy drugs were given concomitantly) [24] . CALGB40603 (NCT00861705) is a randomized phase II trial with a 2×2 factorial design that investigated addition of carboplatin with or without bevacizumab to neoadjuvant weekly paclitaxel followed by dose-dense AC for 443 patients with stage II/III TNBC [25] . The pCR improved from 41 % to 54 % on addition of carboplatin; bevacizumab had no added benefit.
Whereas the GeparSixto and CALGB40603 phase II trials cited above have clearly shown the merit of adding a platinum agent to the systemic treatment of patients with TNBC in the neoadjuvant setting, these trials were clearly underpowered to address disease-free (DFS) and overall (OS) survival. The combined analysis performed by Cortazar et al. [26] could not validate pCR as a surrogate endpoint for improved eventfree survival (EFS) and OS among patients with TNBC. There are several possible reasons for this: the improvement in pCR could simply be a marginally improved response by a subject already destined to do well, and the incremental benefit of some intervention is small overall. It should also be noted that some patients who achieve pCR go on to relapse, and many with residual disease never experience a recurrence. Variability will always be introduced by other factors, including the negative effect of high-risk clinical variables, even among patients achieving pCR, and the positive results of effective drugs given in the adjuvant setting. Ultimately, the reason to treat patients in the (neo)adjuvant setting is prevention of distant recurrence and death from breast cancer. Although the improvement in pCR is certainly encouraging, it may not always result in improvement of DFS and OS. Therefore, studies that are adequately powered to detect a DFS and OS as a result of addition of platinum agents to standard of care chemotherapy are still important and needed. It may, however, be reasonable to consider addition of a platinum agent in the neoadjuvant setting among patients for whom an increase in clinical response to systemic treatment could improve locoregional control (i.e. patients with triple-negative inflammatory breast cancer, or inoperable TNBC at diagnosis).
PARP Inhibition
The poly(ADP-ribose) polymerase 1 (PARP1) enzyme mediates the base excision repair pathway and is critical for repair of single-strand DNA breaks. In BRCA-mutated cells, the PARP enzyme is of particular importance, because these cells are unable to rely on homologous recombination to repair DNA breaks. Inhibition of PARP1 by RNA interference or with chemical inhibitors leads to severe, highly selective toxicity to BRCA1 and BRCA2-defective cells [27] . Sensitivity to PARP inhibition depends on homologous recombination deficiency and not necessarily on inherited BRCA1 or BRCA2 deficiency [28] . PARP1 inhibitors may therefore be an effective therapeutic strategy for treatment of sporadic breast cancers with "BRCAness," including basal-like breast cancers.
Iniparib is not a typical PARP inhibitor, and investigations into potential targets of iniparib and its metabolites are still in progress. An initial phase II report of gemcitabine/carboplatin with or without iniparib among patients with metastatic TNBC was promising, because the reported clinical benefit improved from 33.9 % to 55.7 % (p=0.015) and ORR from 32.3 % to 52.5 % (p=0.023) on addition of iniparib. Interestingly, significant improvements of median progression-free survival (PFS) from 3.6 to 5.9 months (hazard ratio (HR), 0.59; p=0.012) and median OS from 7.7 to 12.3 months (HR, 0.57; p = 0.014) [29] were also seen. However, the confirmatory phase III study which had an almost identical design, did not meet its endpoints for OS and PFS [30] . Around that time, a single-group phase II study of neoadjuvant gemcitabine, carboplatin, and iniparib for patients with TNBC or BRCA 1/2 mutation-associated breast cancer was initiated [31] . An homologous recombination deficiency (HRD) assay was developed as part of this study to identify non-BRCA1/2 mutation carriers with "BRCA-like" cancers who may benefit from DNA repair-targeted treatment strategies. Patients who were BRCA 1 and 2 carriers and patients with higher HRD scores were those with the highest clinical and pathologic complete response.
The PARP inhibitor olaparib was shown to have significant single-agent activity among patients with BRCA-deficient metastatic breast cancer. Overall responses ranged from 22 % (100 mg bid) to 41 % (400 mg bid) with minimum toxicity [32] . A phase II study evaluating olaparib as a single agent for patients with either recurrent high-grade serous or poorly differentiated ovarian carcinoma or TNBC [33] did not report any responses among the patients with TNBC. Several phase III trials investigating the use of olaparib in the metastatic and neoadjuvant setting for patients with BRCA mutations are in progress.
The I-SPY2 trial uses an adaptive study design to treat breast cancer in the neoadjuvant setting; on the basis of the molecular characteristics (biomarker signatures) of a tumor, drugs under investigation are combined (and compared) with standard anthracycline-based and taxane-based chemotherapy to identify novel treatment regimens for different breast cancer subsets. One of the first mature results is from a trial of the combination of standard chemotherapy with and without veliparib, a PARP inhibitor, and carboplatin, for stage II and III patients with TNBC [34] . The primary endpoint of the study, pCR at the time of definitive surgery, was significantly improved by addition of veliparib and carboplatin (52 % vs. 26 %). However, it is unclear if the addition of veliparib to carboplatin contributed in any way to the increase in pCR, because the combination results are quite similar to those for addition of carboplatin only in the GeparSixto and CALGB40603 neoadjuvant trials; definitive studies are in progress.
PI3K Inhibition
Phosphatidylinositol-3 kinase (PI3K) inhibition may also be relevant for basal-like tumors, despite the fact that fewer than 20 % of TNBCs harbor mutations in the PI3K pathway [35] . Preclinical studies of a DNA-damaging agent with PI3K inhibitors have provided rationale for using PI3K inhibitors against non-LAR tumors by demonstrating that, in addition to regulating cell growth, metabolism, and survival, PI3K also stabilizes double strand breaks by interacting with the homologous recombination complex and, in effect, creating a BRCA-deficient state [36] . PI3K blockade promotes homologous recombination deficiency by down-regulating BRCA1/2, creating a BRCA mutantlike tumor state and thus sensitizing BRCA-proficient tumors to PARP inhibition. A phase I study of the pan-PI3K inhibitor BKM120 (Novartis) in combination with the PARP inhibitor olaparib, for patients including those with metastatic TNBC is in progress (NCT01623349).
Similarly, our studies of combinations of PI3K inhibitors and cisplatin have resulted in either additive or synergistic decreases of tumor viability, with significant decreases in pAKT and pS6 levels and concomitant elevation of cleaved PARP. Therefore, we are now conducting a clinical trial in which patients with androgen receptor-negative metastatic TNBC are randomized to chemotherapy with cisplatin with or without a PI3K inhibitor (NCT01918306).
Targeting Luminal Androgen Receptor TNBC
The LAR subtype of TNBC accounts for only 10 % of all TNBCs, and is characterized by androgen receptor signaling and a high incidence of PIK3CA activating mutations. In preclinical studies, strong pre-clinical additive and/or synergistic sensitivity to PI3K inhibitors and to androgen blockers was observed for the LAR subtype [18•] . Patients with this subtype could, potentially, be spared the toxicity of a chemotherapy regimen with expected limited benefit by capitalizing on the potential targets: the PI3K pathway and the androgen receptor. This will be investigated clinically in a phase I/II study of an androgen blocker with a PI3K inhibitor for patients with AR+TNBC, probably in the second quarter of 2014.
Conclusion
TNBC is a heterogeneous and complex disease, and should not be treated a uniformly. Numerous experimental approaches seek to identify "targets" in TNBC: PI3K inhibitors, MEK inhibitors, HSP-90 inhibitors, histone deacetylase inhibitors, and PD-1 (programmed death 1) inhibitors, are a few of the agents under consideration or currently being investigated clinically for treatment of this disease. For most of the targeted therapy being developed, there are still no clinical methods enabling determination of which patients are most likely to benefit or, alternatively, be resistant de novo to these novel agents or drug combinations. The study of biomarkers of drug exposure and sensitivity of metastatic tumors, although feasible, is not easy, because of the inherent difficulty of obtaining sequential tumor samples for research purposes only. Testing novel agents for TNBC in the neoadjuvant or post-neoadjuvant setting is so attractive precisely because the tissue collected at the time of definitive surgery would be enriched with a tumor clone that could be studied for mechanisms of therapeutic resistance.
Ultimately, combining two or more targeted agents with or without chemotherapy may be required to develop a more rational and optimum approach to TNBC treatment, because combination of "complementary" pathway inhibitors would potentially maximize efficacy, and would minimize therapeutic resistance. TNBC subtyping is one of the first steps in the direction of guiding the differential use of novel regimens and assignment of patients with select TNBC subtypes to clinical trials investigating targeted therapy.
